Triple-Negative Breast Cancer Clinical Trials

9 recruiting

Triple-Negative Breast Cancer Trials at a Glance

42 actively recruiting trials for triple-negative breast cancer are listed on ClinicalTrialsFinder across 6 cities in 33 countries. The largest study group is Phase 2 with 20 trials, with the heaviest enrollment activity in Shanghai, Houston, and New York. Lead sponsors running triple-negative breast cancer studies include Fudan University, Cedars-Sinai Medical Center, and BeBetter Med Inc.

Browse triple-negative breast cancer trials by phase

Treatments under study

About Triple-Negative Breast Cancer Clinical Trials

Looking for clinical trials for Triple-Negative Breast Cancer? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Triple-Negative Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Triple-Negative Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 42 trials

Recruiting
Phase 3

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC1,530 enrolled288 locationsNCT06393374
Recruiting

Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer

TNBC - Triple-Negative Breast Cancer
Fudan University300 enrolled1 locationNCT07551050
Recruiting
Phase 2

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

Breast CancerTNBC - Triple-Negative Breast Cancer
Stephen Shiao35 enrolled1 locationNCT05491226
Recruiting
Not Applicable

An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy

Triple-Negative Breast Cancer
Yonsei University40 enrolled2 locationsNCT07525869
Recruiting
Phase 2

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Metastatic Breast CancerHER2-negative Breast CancerMetaplastic Breast Carcinoma+1 more
The Methodist Hospital Research Institute36 enrolled3 locationsNCT05660083
Recruiting
Phase 2

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

TNBC - Triple-Negative Breast CancerEarly Stage Triple-Negative Breast CarcinomaTNBC
Cedars-Sinai Medical Center34 enrolled4 locationsNCT07017673
Recruiting
Phase 1

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Gastric CancerAdvanced Solid TumorTNBC - Triple-Negative Breast Cancer+1 more
SillaJen, Inc.260 enrolled15 locationsNCT05768932
Recruiting
Phase 3

Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer

Triple-Negative Breast Cancer
Fudan University134 enrolled1 locationNCT05806060
Recruiting
Phase 2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+6 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Breast CancerTNBC - Triple-Negative Breast CancerEarly Stage Breast Cancer+2 more
Tempus AI900 enrolled12 locationsNCT07211178
Recruiting
Phase 1Phase 2

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

TNBC - Triple-Negative Breast CancerAdvanced Solid TumorsNSCLC+3 more
Tubulis GmbH250 enrolled16 locationsNCT06657222
Recruiting
Phase 2

Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer

Recurrent Triple-Negative Breast Cancer
Yukinori Ozaki44 enrolled15 locationsNCT06976944
Recruiting
Phase 1Phase 2

Saci Nivo Rela for TNBC

Metastatic Triple-negative Breast Cancer
Yale University60 enrolled1 locationNCT06963905
Recruiting
Not Applicable

NearWave Optical Molecular Monitoring

Breast CancerHER2-negative Breast CancerHER2-positive Breast Cancer+2 more
Indiana University15 enrolled1 locationNCT06744465
Recruiting

Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer

TNBC - Triple-Negative Breast Cancer
University Hospital Tuebingen225 enrolled1 locationNCT05914961
Recruiting
Not Applicable

Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)

Triple-Negative Breast CancerOvarian CancerCervical Cancer+3 more
Institut Curie1,050 enrolled6 locationsNCT03017573
Recruiting
Phase 3

SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC

TNBC - Triple-Negative Breast Cancer
West China Hospital318 enrolled1 locationNCT06627712
Recruiting
Phase 2

Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)

TNBC - Triple-Negative Breast Cancer
First Affiliated Hospital of Zhejiang University37 enrolled2 locationsNCT07351487
Recruiting
Early Phase 1

A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.

Advanced Metastatic Triple-negative Breast Cancer (mTNBC)
Xiaorong Sun15 enrolled1 locationNCT07340424
Recruiting
Phase 3

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.400 enrolled2 locationsNCT07111832